Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

3(30%)

Phase Distribution

Ph phase_1

30%

Ph phase_2

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

3(33.3%)

Phase 2Efficacy & side effects

6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

20.0%

2 of 10 finished

Non-Completion Rate

80.0%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(8)

Detailed Status

Withdrawn5

Terminated3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (33.3%)

Phase 26 (66.7%)

Trials by Status

withdrawn550%

terminated330%

completed220%

Recent Activity

0 active trials

Showing 5 of 10

completedphase_1

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278

withdrawnphase_2

Talabostat in Treating Patients With Metastatic Kidney Cancer

NCT00489710

withdrawnphase_2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773

withdrawnphase_2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

NCT00072540

terminatedphase_2

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03229278Phase 1

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Completed

NCT00489710Phase 2

Talabostat in Treating Patients With Metastatic Kidney Cancer

Withdrawn

NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn

NCT00072540Phase 2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Withdrawn

NCT00258297Phase 2

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Terminated

NCT00040989Phase 2

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

Withdrawn

NCT00124644Phase 1

Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated

NCT00268255Phase 1

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Withdrawn

NCT00483457

Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients

Completed

NCT00265928Phase 2

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10